Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 May 26;8:1193–1210. doi: 10.2147/OTT.S82936

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Lien et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Blood ROS production and cardiac expressions of SOD2, a marker of anti-oxidative stress, and 3-NT, a marker of oxidative stress, in mice under sham, B307, DOX, and B307+DOX treatments.

Notes: (A) Blood ROS production of mice under sham, B307, DOX, and B307+DOX treatments by using a CLD-110 CL detector, (a) blood ROS production in the mice was reduced under B307 treatment but was enhanced under DOX treatment. As to the DOX-treated mice, blood ROS production was reduced under B307 treatment, and (b) total ROS counts in the mice were significantly reduced under B307 treatment but were significantly enhanced under DOX treatment. As to the DOX-treated mice, total ROS counts were significantly reduced under B307 treatment. (B) IHC staining illustrates that cardiac expression levels of SOD2 in the mice were visibly enhanced under oral B307 treatment but were visibly reduced by DOX treatment. As to the DOX-treated mice, cardiac expression levels of sOD2 were visibly enhanced under oral B307 treatment. On the other hand, cardiac expression levels of 3-nT of mice were visibly reduced under oral B307 treatment but were visibly enhanced under DOX treatment. As to the DOX-treated mice, cardiac expression levels of 3-NT were visibly reduced under oral B307 treatment. (C) Western blotting analysis shows the following: (a) expression levels of cardiac SOD2 and 3-NT under sham, B307, DOX, and B307+DOX treatments and (b) quantified SOD2 levels in the heart tissue of the mice were significantly enhanced under oral B307 treatment but were significantly reduced under DOX treatment. As to the DOX-treated mice, quantified SOD2 levels in heart tissue were significantly enhanced under oral B307 treatment. On other hand, quantified 3-NT levels in the heart tissue of mice were significantly reduced under oral B307 treatment, but were significantly enhanced under DOX treatment. As to the DOX-treated mice, quantified 3-NT levels in the heart tissue were significantly reduced under oral B307 treatment. The number of mice under sham, B307, DOX, and B307+DOX treatments was six for each group. Values are mean ± SEM (*P<0.05, **P<0.01, two-way ANOVA followed by a Student–Newman–Keuls multiple comparisons posttest).

Abbreviations: ROS, reactive oxygen species; CL, luminol chemiluminescence; DOX, doxorubicin; 3-NT, neurotrophin-3; SOD2, superoxide dismutase 2; kDa, kilodalton; IHC, immunohistochemical; SEM, standard error of the mean; ANOVA, analysis of variance.